HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Wraps Up Alcon Ownership, Forms New Eye Care Unit

This article was originally published in The Tan Sheet

Executive Summary

Novartis will create an eye care division, its second-largest unit and the fifth growth platform in its health care portfolio, with full ownership of Alcon, the world's largest eye care company.

You may also be interested in...



Novartis Makes Room For OTC Division Head On Executive Committee

Novartis gives its OTC unit a direct line to the chief executive in an organizational realignment designed to strengthen and streamline the consumer businesses.

Sales & Earnings In Brief

P&G sees sign of North American recovery

Novartis Weighs Sweetening Buyout Offer As Alcon Shareholders Fight Back

Independent Alcon shareholders have held out for months for a per-share buyout offer that's closer to the price Novartis is paying for the majority of the company. If Novartis wants to avoid an extended legal battle, it may accede to their demands

Related Content

Topics

UsernamePublicRestriction

Register

RS134774

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel